Crohn Disease  >>  Artlegia (olokizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Artlegia (olokizumab) / R-Pharm
NCT01635621 / 2011-002517-11: A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease

Withdrawn
2
0
Europe
Olokizumab (OKZ), CDP6038, Placebo
UCB BIOSCIENCES GmbH
Crohn's Disease
08/13
08/13

Download Options